In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. He focuses on why, despite the positive trends, Dendreon is far from out of the woods. Watch and find out why investors who bid up shares as much as 30% intraday on Friday may be missing the bigger picture.
Breaking down Dendreon's Q3 results.
David Williamson owns shares of Johnson & Johnson. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
A Bull Market Is Coming: 2 Top Stocks to Buy Hand Over Fist
1 Promising Stock Down 66% That Could Skyrocket in 2024
Better Growth Stock: CRISPR Therapeutics vs. Invitae
This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
512%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.